What Researchers Did
Researchers conducted a pilot phase I study to evaluate the safety of Fluosol and hyperbaric oxygen (HBO) as an adjunct to radiation therapy in 20 patients with malignant gliomas.
What They Found
Of the 20 patients enrolled, 16 completed the treatment, with no interruptions due to toxicity. The study found that escalating Fluosol doses from 42 ml/kg to 80 ml/kg, combined with hyperbaric oxygen and radiation, did not increase HBO-related toxicities or cause significant chronic toxicities.
What This Means for Canadian Patients
This pilot study suggests that Fluosol and hyperbaric oxygen can be safely added to radiation therapy for malignant gliomas. While further research is needed to confirm efficacy, this approach could potentially offer a new way to enhance tumor oxygenation and radiation response for Canadian patients.
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
As a pilot phase I study with a small sample size, this research primarily assessed safety and did not evaluate the efficacy of the treatment.